A significant treatment benefit is observed in men with metastatic hormone-naïve prostate cancer treated with androgen deprivation therapy combined with abiraterone acetate and prednisolone, irrespective of being designated as having a `low` or a `high` risk by the current treatment criteria. This consistent result applies to all efficacy outcome measures.